CN105595359A - Positioning and controlled-release microcapsule probiotics and preparation method thereof - Google Patents
Positioning and controlled-release microcapsule probiotics and preparation method thereof Download PDFInfo
- Publication number
- CN105595359A CN105595359A CN201610064261.9A CN201610064261A CN105595359A CN 105595359 A CN105595359 A CN 105595359A CN 201610064261 A CN201610064261 A CN 201610064261A CN 105595359 A CN105595359 A CN 105595359A
- Authority
- CN
- China
- Prior art keywords
- positioning
- capsule
- probio
- slow release
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 14
- 239000006041 probiotic Substances 0.000 title abstract description 12
- 238000013270 controlled release Methods 0.000 title abstract 5
- 238000001179 sorption measurement Methods 0.000 claims abstract description 22
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 21
- 239000000725 suspension Substances 0.000 claims abstract description 20
- 230000002378 acidificating effect Effects 0.000 claims abstract description 16
- 238000000855 fermentation Methods 0.000 claims abstract description 15
- 230000004151 fermentation Effects 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 238000003756 stirring Methods 0.000 claims abstract description 12
- 230000001580 bacterial effect Effects 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 57
- 239000002253 acid Substances 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 18
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 16
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 12
- -1 compound ion Chemical class 0.000 claims description 12
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 12
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 12
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 11
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 11
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 11
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 11
- 241001608472 Bifidobacterium longum Species 0.000 claims description 10
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 10
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 10
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000000853 adhesive Substances 0.000 claims description 9
- 230000001070 adhesive effect Effects 0.000 claims description 9
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 9
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 8
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 8
- 239000000347 magnesium hydroxide Substances 0.000 claims description 8
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims description 7
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 230000005526 G1 to G0 transition Effects 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims description 3
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 3
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 claims description 2
- 229960003487 xylose Drugs 0.000 claims description 2
- 240000002605 Lactobacillus helveticus Species 0.000 claims 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims 1
- 229940054346 lactobacillus helveticus Drugs 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 239000003833 bile salt Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 230000000529 probiotic effect Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract 4
- 241001052560 Thallis Species 0.000 abstract 3
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 210000004211 gastric acid Anatomy 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- 230000000968 intestinal effect Effects 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 10
- 210000004051 gastric juice Anatomy 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 238000004088 simulation Methods 0.000 description 8
- 238000009395 breeding Methods 0.000 description 7
- 230000001488 breeding effect Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000011162 core material Substances 0.000 description 4
- 229960001305 cysteine hydrochloride Drugs 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 206010011732 Cyst Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Abstract
The invention relates to the technical field of biology and particularly relates to positioning and controlled-release microcapsule probiotics and a preparation method thereof. The positioning and controlled-release microcapsule probiotics provided by the invention sequentially comprise a thallus layer, an acidic embedded adsorption layer and a compound ion layer form inside to outside, wherein the thallus layer comprises probiotics and prebiotics; the acidic embedded adsorption layer comprises acidic substances; and the compound ion layer comprises alkaline substances. The preparation method provided by the invention comprises the following steps: after activating probiotic strains, culturing; and after growing to a stable period, stopping fermentation; centrifuging and then collecting thalli; adding the prebiotics into the thalli to obtain bacterial suspension; after mixing and stirring the bacterial suspension and the acidic substances at a ratio, mixing and stirring the mixture with the alkaline substances at a ratio to form double-layered microcapsule bacterial liquid; and carrying out freeze-drying treatment on the double-layered microcapsule bacterial liquid to obtain the positioning and controlled-release microcapsule probiotics. According to the positioning and controlled-release microcapsule probiotics and the preparation method thereof, provided by the invention, the probiotics are effectively protected; the probiotic thalli can be released at a target site, so that the probiotics are free of influences of external factors including gastric acid, bile salt, enzymes and the like in the serving process.
Description
Technical field
The present invention relates to biological technical field, relate in particular to a kind of positioning and slow release micro-capsule probio and preparation side thereofMethod.
Background technology
Positioning and slow release micro-capsule probio is probio protection, enteron aisle field planting and the breeding of micro-ecological industry-leadingTechnology. So-called microcapsule technology, utilizes natural or synthetic high-polymer encapsulated material exactly, by solid,The coated formation of small capsule nuclear matter liquid or even gas diameter is (common within the scope of 1～5000 μ mBetween 5～400 μ m) a kind of have semi permeability or sealing cyst membrane microencapsulation technology, can protectThe capsule heart is not affected by external environment. The cyst membrane of microcapsules can be both individual layer, can be also double-deck orSandwich construction, and the coated capsule core material of cyst membrane can be both monokaryon, can be also multinuclear. Micro-The choosing of coating material in capsule technology, need determine according to the specific requirement of specific product conventionally, has both required packingMaterial can form one deck and have the film of adhesion on core material, but also requires to make coating material notWith core material generation chemical reaction, also to consider simultaneously product permeability, hygroscopicity, stability,The factor such as dissolubility and clarity. In food processing industry, selected coating material is mainly with water at presentGlue class, starch, casein, alginate and the cellulose derivative of dissolubility, for example Arabic gum, marine algaHydrochlorate, carboxymethyl cellulose and casein-sodium etc. are main.
Probio is the microorganism formulation of living, and can improve host's intestinal microecology balance. Reside in human bodyProbio in enteron aisle can suppress in harmful microorganism and food pathogenic microorganism as the growth of salmonella etc.Probio passes through produce the acceptor of acid, bacteriocin and competition intestinal mucosa and improve immunity of organisms in enteron aisleBring into play effect. Probio is embedded in wall material with positioning and slow release microcapsule technology, also can reduces extraneous ringThe damage of border to cell, and probio efficiently can be located and discharges and breeding at enteron aisle. But maximum limit howDegree ground protection probio, discharges probio thalline at target site, makes probio avoid stomach in edible processThe impact of the extraneous factors such as acid, bile salt, enzyme, becomes the difficult problem of positioning and slow release micro-capsule probio technology.
Summary of the invention
For solving the problems of the technologies described above, the object of this invention is to provide a kind of effectively protection probio, in targetSite discharges probio thalline, make probio avoid in edible process hydrochloric acid in gastric juice, bile salt, enzyme etc. extraneous because ofPositioning and slow release micro-capsule probio of element impact and preparation method thereof.
First aspect present invention provides a kind of positioning and slow release micro-capsule probio, comprise successively from the inside to the outside thalline layer,Acid embedding adsorption layer and compound ion layer; Described thalline layer comprises probio and prebiotics, described acidProperty embedding adsorption layer comprises acidic materials, and described compound ion layer comprises alkaline matter.
It should be noted that probio is the active microorganism that a class is useful to host, is to be colonizated in human body intestinesIn road, reproductive system, improve host's microecological balance, bring into play useful work thereby can produce definite health efficacyWith active beneficial microorganism general name. In human body, animal body, useful bacterium or fungi mainly contains: butyric acidClostridium, lactic acid bacteria, Bifidobacterium, lactobacillus acidophilus, actinomyces, saccharomycete etc. Indication in the present inventionProbio, should be including, but not limited to bifidobacterium infantis, bifidobacterium adolescentis, bifidobacterium breve, lengthBifidobacterium, bifidobacterium lactis, bifidobacterium bifidum, lactobacillus acidophilus, Lactobacillus plantarum, Switzerland's breast barOne or more in bacterium, lactobacillus reuteri.
The positioning and slow release micro-capsule probio of indication in the present invention, when it passes through human gastric juice, outside micro-capsule probioIn the basic species mass-energy of layer and hydrochloric acid in gastric juice, protection probio is not damaged by hydrochloric acid in gastric juice, arrives when human body intestinal canal micro-capsuleIn acid mass-energy in the acid embedding adsorption layer of probio and the enteron aisle alkaline environment such as bile salt, discharge high livingThe probio of property, and probio is colonizated in to intestinal epithelial cell, under the effect of prebiotics, probio obtainsWith amount reproduction optionally, promote intestinal beneficial bacterium growth.
It should be noted that prebiotics (Prebiotics) is a kind of dietary supplements, by optionally stingingSwash the growth of bacterium in a kind of or minority kind bacterium colony with active, thereby and host is produced to wholesome effect improvementHost's health can not be digested food composition. Successfully prebiotics should be when by UGI, largePart is digested and can be by gut flora fermented. The most important thing is that it just stimulates the life of profitable strainLong, instead of have the harmful bacteria of potential pathogenic or corrupt activity.
It has been generally acknowledged that, prebiotics provides " food " to probio, and can be decomposed and absorb by beneficial bacteria in enteron aisle,Promote beneficial bacteria growth and breeding. As Oilgosaccharkdes, be the prebiotics that promotes bifidobacterium growth in intestines.And isomalto-oligosaccharide and FOS are representatives the most excellent in prebiotics.
Further, in the present invention, the described prebiotics of indication comprises galactooligosaccharide, FOS, oligomericOne or more in wood sugar and isomalto-oligosaccharide.
Further, described prebiotics comprises galactooligosaccharide, the 10-30% of 20-30% in mass fractionThe xylo-oligosaccharide of FOS, 20-40% and the isomalto-oligosaccharide of 20-35%; Wherein, oligomeric galaSugar adopts the powderous preparations that mass fraction is 70%, and FOS adopts the powderous preparations that mass fraction is 95%.
Further, described acid embedding adsorption layer also comprises adhesive, and described acidic materials comprise amino acidAnd aliphatic acid, described adhesive comprises one or both in starch and cyclodextrin.
It should be noted that described acid embedding adsorption layer, in its role is to and the alkaline environment of enteron aisle,And positioning and slow release prebiotics and probio, every acidic materials and the adhesive that can realize above-mentioned functions, allProtection scope of the present invention be should fall into, and amino acid, aliphatic acid, starch and cyclodextrin are not limited to; ItsIn, the effect of amino acid and aliphatic acid be to provide acid ion with in and alkaline environment, starch or cyclodextrinEffect be bonding acidic materials with form prebiotics wherein of acid embedding adsorption layer emulsification embedding andProbio.
Further, described alkaline matter comprises in calcium carbonate, magnesium hydroxide, sodium acid carbonate, calcium chlorideOne or more.
It should be noted that the alkaline matter in described compound ion layer, its role is to micro-capsule probio warpWhile crossing stomach, in and hydrochloric acid in gastric juice with prevent hydrochloric acid in gastric juice enter micro-capsule core reduce probiotic active. Every can realizationThe alkaline matter of this function, all should fall into protection scope of the present invention; In concrete use procedure, this alkaliProperty material should meet, can not cause damage for intestines and stomach endepidermis cell, effectively in and hydrochloric acid in gastric juice, simultaneouslyDuring the thickness of compound ion layer is enough to and hydrochloric acid in gastric juice, in the time that micro-capsule enters enteron aisle alkaline environment, again can simultaneouslyTo discharge inner acid embedding adsorption layer.
Second aspect present invention provides a kind of positioning and slow release micro-capsule probio preparation method, comprises the following steps:
S1, thalline preparation: will after the activation of probio bacterial classification, cultivate, grow to and stop fermentation stationary phase, centrifugalRear collection thalline;
S2, collecting cells: in thalline, add prebiotics to obtain bacteria suspension;
S3, the preparation of acid embedding adsorption layer: by bacteria suspension and stirring proportional mixing of embedding medium containing acidic materialsMix, obtain individual layer micro-capsule bacterium liquid;
S4, the preparation of compound ion layer: by individual layer micro-capsule bacterium liquid and the proportional mix and blend of alkaline matter, obtainDouble-layer microcapsule bacterium liquid;
S5, the preparation of bacterium powder: double-layer microcapsule bacterium liquid frozen dried is made.
Further, described probio comprise bifidobacterium infantis, bifidobacterium adolescentis, bifidobacterium breve,Bifidobacterium longum, bifidobacterium lactis, bifidobacterium bifidum, lactobacillus acidophilus, Lactobacillus plantarum, Switzerland's breastOne or more in bacillus, lactobacillus reuteri.
Further, described prebiotics comprises that galactooligosaccharide, FOS, xylo-oligosaccharide and different Fructus Hordei Germinatus are lowOne or more in glycan.
Further, described prebiotics comprises galactooligosaccharide, the 10-30% of 20-30% in mass fractionThe xylo-oligosaccharide of FOS, 20-40% and the isomalto-oligosaccharide of 20-35%.
Further, described embedding medium comprises acidic materials and adhesive, and described acidic materials comprise amino acidAnd aliphatic acid, described adhesive comprises one or both in starch and cyclodextrin.
Concrete, in described step S3, the mixed proportion of bacteria suspension and embedding medium is 1:1-1:5.
Further, described alkaline matter comprises in calcium carbonate, magnesium hydroxide, sodium acid carbonate, calcium chlorideOne or more.
Concrete, in described step S4, the mixed proportion of individual layer micro-capsule bacterium liquid and alkaline matter is 1:1-1:3.
By such scheme, the present invention at least has the following advantages: the positioning and slow release micro-capsule benefit that the present invention makesRaw bacterium freeze-dried powder can well tolerate the impact of hydrochloric acid in gastric juice, bile salt, and can rapidly and efficiently be colonizated in gut epitheliumCell and amount reproduction, promote intestinal beneficial bacterium growth, for the exploitation of probiotics preparation product and food,The application of the industries such as medicine, health products provides efficient freeze-dried powder technology of preparing.
Above-mentioned explanation is only the general introduction of technical solution of the present invention, in order to better understand technology of the present inventionMeans, and can being implemented according to the content of description, below describe in detail with preferred embodiment of the present inventionAs rear.
Detailed description of the invention
Below in conjunction with embodiment, the specific embodiment of the present invention is described in further detail. Below implementExample is used for illustrating the present invention, but is not used for limiting the scope of the invention.
Embodiment 1: positioning and slow release micro-capsule bifidobacterium infantis and preparation thereof
The bifidobacterium infantis filtering out is seeded to 37 DEG C of activation culture 24h in 10% milk pipe, then turnsBe connected in triangular flask and spread cultivation and cultivate 12h, OD600> be seeded in fermentation tank culture medium 37 DEG C after 2.5 and cultivate 10h,Culture medium consist of lactose 2%, yeast extract 0.5%, peptone 1%, corn steep liquor 0.8%, brewer's wort 0.5%,Cysteine hydrochloride 0.06%, Tween-80 0.5%, diammonium hydrogen citrate 0.06%. Stream during the fermentationAdding NaOH alkali lye and regulate Ph4.5 to carry out high density fermentation, is OD when growing to early stage stationary phase600ApproximatelyEqual cooling in 7 o'clock and stop fermentation, then collect thalline through the centrifugal 20min of tube centrifuge, in bacterium mud, addMade by 25% galactooligosaccharide, 15% FOS, 30% xylo-oligosaccharide and 30% isomalto-oligosaccharideProtective agent, emulsification embedding 15min, obtains bacteria suspension.
Bacteria suspension mixes with the ratio of 1:3 with acid embedding adsorption layer, under normal temperature, stirs with 200rpm/min20min. Acid embedding adsorption layer is made up of amino acid, aliphatic acid and starch. Again with the ratio of 1:2.5 with multipleClose sheath and mix, under normal temperature, 200rpm/min stirs 20min, and compound ion layer is by 0.5% calcium carbonate, 0.3%Magnesium hydroxide and 0.1% sodium acid carbonate composition.
Above-mentioned bacteria suspension is pre-freeze 3h in the environment of-80 DEG C, then is at-50 DEG C at condenser temperature, and vacuum isUnder 5-15pa, dry 40-60h, makes bifidobacterium infantis positioning and slow release micro-capsule bacterium powder.
The bifidobacterium infantis positioning and slow release micro-capsule bacterium powder making has good positioning and slow release ability and breeding energyPower. Simulation enteron aisle experimental design scheme: watery hydrochloric acid is acidified to the SGF of pH2.5, effect 2h; Hydrogen-oxygenChange the simulated intestinal fluid that sodium regulates pH8.0, effect 12h; Be seeded to MRS medium culture 12h, viable bacteria meterNumber. By positioning and slow release micro-capsule bifidobacterium infantis with do not position slow-releasing microcapsule probio and contrast, bodyOuter simulated experiment situation is as follows,
| Experimental group | Viable count cfu/ml |
| Positioning and slow release micro-capsule bifidobacterium infantis | 2.5*1010 |
| No-fix slow-releasing microcapsule bifidobacterium infantis | 3.7*109 |
Positioning and slow release micro-capsule bifidobacterium infantis bacterium powder under simulation intestinal environment effect, viable count apparently higher thanDo not position slow-releasing microcapsule, illustrate that its stomach juice-resistant, resistance to bile alkaline and absorption fertility have a remarkable effectReally.
Embodiment 2: positioning and slow release micro-capsule bifidobacterium longum and preparation thereof
The bifidobacterium longum filtering out is seeded to 37 DEG C of activation culture 24h in 10% milk pipe, then transfersCultivate 12h, OD to spreading cultivation in triangular flask600> be seeded in fermentation tank culture medium 37 DEG C after 2.5 and cultivate 10h,Culture medium consist of lactose 2%, yeast extract 0.5%, peptone 1%, corn steep liquor 0.8%, brewer's wort 0.5%,Cysteine hydrochloride 0.06%, Tween-80 0.5%, diammonium hydrogen citrate 0.06%. Stream during the fermentationAdding NaOH alkali lye and regulate Ph4.5 to carry out high density fermentation, is OD when growing to early stage stationary phase600ApproximatelyEqual cooling in 7 o'clock and stop fermentation, then collect thalline through the centrifugal 20min of tube centrifuge, in bacterium mud, addMade by 30% galactooligosaccharide, 10% FOS, 25% xylo-oligosaccharide and 35% isomalto-oligosaccharideProtective agent, emulsification embedding 15min, obtains bacteria suspension.
Bacteria suspension mixes with the ratio of 1:5 with acid embedding adsorption layer, under normal temperature, stirs with 200rpm/min20min. Acid embedding adsorption layer is made up of amino acid, aliphatic acid and starch. Again with the ratio of 1:3 and compoundSheath mixes, and under normal temperature, 200rpm/min stirs 20min, and compound ion layer is by 0.5% calcium carbonate, 0.3%Magnesium hydroxide and 0.1% sodium acid carbonate composition.
Above-mentioned bacteria suspension is pre-freeze 3h in the environment of-80 DEG C, then is at-50 DEG C at condenser temperature, and vacuum isUnder 5-15pa, dry 40-60h, makes bifidobacterium longum positioning and slow release micro-capsule bacterium powder.
The bifidobacterium longum positioning and slow release micro-capsule bacterium powder making has good positioning and slow release ability and breeding energyPower. Simulation enteron aisle experimental design scheme: watery hydrochloric acid is acidified to the SGF of pH2.5, effect 2h; Hydrogen-oxygenChange the simulated intestinal fluid that sodium regulates pH8.0, effect 12h; Be seeded to MRS medium culture 12h, viable bacteria meterNumber. By positioning and slow release micro-capsule bifidobacterium longum with do not position slow-releasing microcapsule probio and contrast, externalSimulated experiment situation is as follows,
| Experimental group | Viable count cfu/ml |
| Positioning and slow release micro-capsule bifidobacterium longum | 4.3*1010 |
| No-fix slow-releasing microcapsule bifidobacterium longum | 3.4*109 |
Positioning and slow release micro-capsule bifidobacterium longum bacterium powder is under simulation intestinal environment effect, and viable count is not apparently higher thanPosition slow-releasing microcapsule, illustrate that its stomach juice-resistant, resistance to bile alkaline and absorption fertility have remarkable result.
Embodiment 3: positioning and slow release micro-capsule lactobacillus acidophilus and preparation thereof
The lactobacillus acidophilus filtering out is seeded to 37 DEG C of activation culture 24h in 10% milk pipe, then transfersCultivate 10h, OD to spreading cultivation in triangular flask600> be seeded in fermentation tank culture medium 37 DEG C after 2.0 and cultivate 6h,Culture medium consists of glucose sugar 2%, yeast extract 0.5%, peptone 1%, beef extract powder 1.0%, acetic acidSodium 0.5%, cysteine hydrochloride 0.06%, Tween-80 0.5%, diammonium hydrogen citrate 0.06%. In fermentationIn process, stream adds NaOH alkali lye and regulates Ph5.5 to carry out high density fermentation, when growing to stationary phase early stageOD600Approximate greatly cooling in 10 o'clock and stop fermentation, then collect thalline through the centrifugal 20min of tube centrifuge,In bacterium mud, add low by 30% galactooligosaccharide, 20% FOS, 25% xylo-oligosaccharide and 25% different Fructus Hordei GerminatusThe protective agent that glycan is made, emulsification embedding 15min, obtains bacteria suspension.
Bacteria suspension mixes with the ratio of 1:2 with acid embedding adsorption layer, under normal temperature, stirs with 200rpm/min20min. Acid embedding adsorption layer is made up of amino acid, aliphatic acid and cyclodextrin. Again with the ratio of 1:2 with multipleClose sheath and mix, under normal temperature, 200rpm/min stirs 20min, and compound ion layer is by 0.1% calcium carbonate, 0.3%Magnesium hydroxide and 0.03% calcium chloride composition.
Above-mentioned bacteria suspension is pre-freeze 3h in the environment of-80 DEG C, then is at-50 DEG C at condenser temperature, and vacuum isUnder 5-15pa, dry 40-60h, makes lactobacillus acidophilus positioning and slow release micro-capsule bacterium powder.
The lactobacillus acidophilus positioning and slow release micro-capsule bacterium powder making has good positioning and slow release ability and breeding energyPower. Simulation enteron aisle experimental design scheme: watery hydrochloric acid is acidified to the SGF of pH2.5, effect 2h; Hydrogen-oxygenChange the simulated intestinal fluid that sodium regulates pH8.0, effect 12h; Be seeded to MRS medium culture 12h, viable bacteria meterNumber. By positioning and slow release micro-capsule lactobacillus acidophilus with do not position slow-releasing microcapsule probio and contrast, externalSimulated experiment situation is as follows,
| Experimental group | Viable count cfu/ml |
| Positioning and slow release micro-capsule lactobacillus acidophilus | 5.2*1010 |
| No-fix slow-releasing microcapsule lactobacillus acidophilus | 1.1*109 |
Positioning and slow release micro-capsule lactobacillus acidophilus bacterium powder is under simulation intestinal environment effect, and viable count is not apparently higher thanPosition slow-releasing microcapsule, illustrate that its stomach juice-resistant, resistance to bile alkaline and absorption fertility have remarkable result.
Embodiment 4: positioning and slow release micro-capsule Lactobacillus plantarum and preparation thereof
The Lactobacillus plantarum filtering out is seeded to 37 DEG C of activation culture 24h in 10% milk pipe, then transfersCultivate 10h, OD to spreading cultivation in triangular flask600> be seeded in fermentation tank culture medium 37 DEG C after 2.0 and cultivate 6h,Culture medium consists of glucose sugar 2%, yeast extract 0.5%, peptone 1%, beef extract powder 1.0%, acetic acidSodium 0.5%, cysteine hydrochloride 0.06%, Tween-80 0.5%, diammonium hydrogen citrate 0.06%. In fermentationIn process, stream adds NaOH alkali lye and regulates Ph5.5 to carry out high density fermentation, when growing to stationary phase early stageOD600Approximate greatly cooling in 10 o'clock and stop fermentation, then collect thalline through the centrifugal 20min of tube centrifuge,In bacterium mud, add low by 20% galactooligosaccharide, 30% FOS, 30% xylo-oligosaccharide and 20% different Fructus Hordei GerminatusThe protective agent that glycan is made, emulsification embedding 15min, obtains bacteria suspension.
Bacteria suspension mixes with the ratio of 1:1 with acid embedding adsorption layer, under normal temperature, stirs with 200rpm/min20min. Acid embedding adsorption layer is made up of amino acid, aliphatic acid and cyclodextrin. Again with the ratio of 1:1 with multipleClose sheath and mix, under normal temperature, 200rpm/min stirs 20min, and compound ion layer is by 0.1% calcium carbonate, 0.3%Magnesium hydroxide and 0.03% calcium chloride composition.
Above-mentioned bacteria suspension is pre-freeze 3h in the environment of-80 DEG C, then is at-50 DEG C at condenser temperature, and vacuum isUnder 5-15pa, dry 40-60h, makes Lactobacillus plantarum positioning and slow release micro-capsule bacterium powder.
The Lactobacillus plantarum positioning and slow release micro-capsule bacterium powder making has good positioning and slow release ability and breeding energyPower. Simulation enteron aisle experimental design scheme: watery hydrochloric acid is acidified to the SGF of pH2.5, effect 2h; Hydrogen-oxygenChange the simulated intestinal fluid that sodium regulates pH8.0, effect 12h; Be seeded to MRS medium culture 12h, viable bacteria meterNumber. By positioning and slow release micro-capsule Lactobacillus plantarum with do not position slow-releasing microcapsule probio and contrast, externalSimulated experiment situation is as follows,
| Experimental group | Viable count cfu/ml |
| Positioning and slow release micro-capsule Lactobacillus plantarum | 1.5*1010 |
| No-fix slow-releasing microcapsule Lactobacillus plantarum | 4.6*109 |
Positioning and slow release micro-capsule Lactobacillus plantarum bacterium powder is under simulation intestinal environment effect, and viable count is not apparently higher thanPosition slow-releasing microcapsule, illustrate that its stomach juice-resistant, resistance to bile alkaline and absorption fertility have remarkable result.
The above is only the preferred embodiment of the present invention, is not limited to the present invention, it should be pointed out thatFor those skilled in the art, do not departing under the prerequisite of the technology of the present invention principle, alsoCan make some improvement and modification, these improve and modification also should be considered as protection scope of the present invention.
Claims (10)
1. a positioning and slow release micro-capsule probio, is characterized in that: comprise successively from the inside to the outside thalline layer, acidProperty embedding adsorption layer and compound ion layer; Described thalline layer comprises probio and prebiotics, described acidityEmbedding adsorption layer comprises acidic materials, and described compound ion layer comprises alkaline matter.
2. positioning and slow release micro-capsule probio according to claim 1, is characterized in that: described probioComprise bifidobacterium infantis, bifidobacterium adolescentis, bifidobacterium breve, bifidobacterium longum, bifidobacterium lactis,In bifidobacterium bifidum, lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus helveticus, lactobacillus reuteri oneKind or multiple.
3. positioning and slow release micro-capsule probio according to claim 1, is characterized in that: described prebioticsComprise one or more in galactooligosaccharide, FOS, xylo-oligosaccharide and isomalto-oligosaccharide.
4. positioning and slow release micro-capsule probio according to claim 3, is characterized in that: described prebioticsComprise FOS, 20-40% oligomeric of galactooligosaccharide, the 10-30% of 20-30% in mass fractionThe isomalto-oligosaccharide of wood sugar and 20-35%.
5. positioning and slow release micro-capsule probio according to claim 1, is characterized in that: described acid bagBury adsorption layer and also comprise adhesive, described acidic materials comprise amino acid and aliphatic acid, and described adhesive comprisesOne or both in starch and cyclodextrin.
6. positioning and slow release micro-capsule probio according to claim 1, is characterized in that: described basic speciesMatter comprises one or more in calcium carbonate, magnesium hydroxide, sodium acid carbonate, calcium chloride.
7. a positioning and slow release micro-capsule probio preparation method, is characterized in that: comprise the following steps:
S1, thalline preparation: will after the activation of probio bacterial classification, cultivate, grow to and stop fermentation stationary phase, centrifugalRear collection thalline;
S2, collecting cells: in thalline, add prebiotics to obtain bacteria suspension;
S3, the preparation of acid embedding adsorption layer: by bacteria suspension and stirring proportional mixing of embedding medium containing acidic materialsMix, obtain individual layer micro-capsule bacterium liquid;
S4, the preparation of compound ion layer: by individual layer micro-capsule bacterium liquid and the proportional mix and blend of alkaline matter, obtainDouble-layer microcapsule bacterium liquid;
S5, the preparation of bacterium powder: double-layer microcapsule bacterium liquid frozen dried is made;
Wherein,
Described prebiotics comprises one in galactooligosaccharide, FOS, xylo-oligosaccharide and isomalto-oligosaccharideKind or multiple;
Described embedding medium comprises acidic materials and adhesive, and described acidic materials comprise amino acid and aliphatic acid,Described adhesive comprises one or both in starch and cyclodextrin;
Described alkaline matter comprises one or more in calcium carbonate, magnesium hydroxide, sodium acid carbonate, calcium chloride.
8. positioning and slow release micro-capsule probio preparation method according to claim 7, is characterized in that: instituteState prebiotics comprises 20-30% galactooligosaccharide, the FOS of 10-30%, 20-40% in mass fractionXylo-oligosaccharide and the isomalto-oligosaccharide of 20-35%.
9. positioning and slow release micro-capsule probio preparation method according to claim 7, is characterized in that: instituteState in step S3, the mixed proportion of bacteria suspension and embedding medium is 1:1-1:5.
10. positioning and slow release micro-capsule probio preparation method according to claim 7, is characterized in that:In described step S4, the mixed proportion of individual layer micro-capsule bacterium liquid and alkaline matter is 1:1-1:3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610064261.9A CN105595359A (en) | 2016-01-29 | 2016-01-29 | Positioning and controlled-release microcapsule probiotics and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610064261.9A CN105595359A (en) | 2016-01-29 | 2016-01-29 | Positioning and controlled-release microcapsule probiotics and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105595359A true CN105595359A (en) | 2016-05-25 |
Family
ID=55976162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610064261.9A Pending CN105595359A (en) | 2016-01-29 | 2016-01-29 | Positioning and controlled-release microcapsule probiotics and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105595359A (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106417614A (en) * | 2016-11-22 | 2017-02-22 | 杭州益儒信息科技有限公司 | Probiotic slow releasing device |
| CN106667257A (en) * | 2016-11-22 | 2017-05-17 | 杭州益儒信息科技有限公司 | Water dispenser with probiotic slow release device |
| CN107549420A (en) * | 2017-10-30 | 2018-01-09 | 浙江同创越诚健康科技有限公司 | Probiotics candy and preparation method thereof |
| CN109182397A (en) * | 2018-09-18 | 2019-01-11 | 北京大伟嘉生物技术股份有限公司 | A method of improving reuterin yield |
| CN109700781A (en) * | 2019-02-25 | 2019-05-03 | 绍兴同创生物科技有限公司 | A kind of probiotic microcapsule and preparation method thereof targeting enteron aisle |
| CN109846043A (en) * | 2017-11-30 | 2019-06-07 | 内蒙古伊利实业集团股份有限公司 | A kind of colon sustained release probiotics and preparation method thereof |
| CN110123790A (en) * | 2019-05-17 | 2019-08-16 | 南京望知星医药科技有限公司 | A kind of clarithromycin slow-release micro-capsule and preparation method thereof |
| CN110432495A (en) * | 2018-05-03 | 2019-11-12 | 内蒙古伊利实业集团股份有限公司 | A kind of probiotics preparation and preparation method thereof of acidproof resistance to bile salt |
| CN110604307A (en) * | 2019-08-02 | 2019-12-24 | 嘉必优生物技术（武汉）股份有限公司 | Probiotic microcapsule powder and preparation method and application thereof |
| CN110771898A (en) * | 2019-11-08 | 2020-02-11 | 厦门九和良方医药科技有限公司 | Probiotic microcapsule, preparation method and application thereof |
| CN111280449A (en) * | 2020-02-11 | 2020-06-16 | 浙江华康药业股份有限公司 | Intestinal slow-release sugar alcohol additive and preparation method and application thereof |
| CN111297911A (en) * | 2020-02-26 | 2020-06-19 | 青岛诺森生物技术有限责任公司 | Slow-release stress-resistant probiotic crystal ball and preparation method thereof |
| CN111317140A (en) * | 2020-05-06 | 2020-06-23 | 永安康健药业（武汉）有限公司 | Bile salt-resistant and gastric acid-resistant probiotic preparation as well as preparation method and application thereof |
| CN111920050A (en) * | 2020-09-01 | 2020-11-13 | 上海应用技术大学 | Double-layer microcapsule for regulating intestinal flora and preparation method thereof |
| CN115500516A (en) * | 2022-09-28 | 2022-12-23 | 江苏恒康生物科技有限公司 | Probiotic slow-release carrier, slow-release dropping pill, and preparation method and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1916161A (en) * | 2006-09-08 | 2007-02-21 | 肖雯娟 | Embedding protection method for beneficial bacteria of intestinal tract |
| CN101148642A (en) * | 2006-09-19 | 2008-03-26 | 国家淀粉及化学投资控股公司 | Probiotic/non-probiotic combinations |
| US20080138419A1 (en) * | 2003-04-15 | 2008-06-12 | Animal Technology Institute Taiwan | Method for preparing an orally administrable formulation for controlled release |
| CN101683604A (en) * | 2009-08-21 | 2010-03-31 | 黑龙江大学 | Method for preparing lactobacillus microcapsules |
| CN102960598A (en) * | 2012-11-19 | 2013-03-13 | 陕西科技大学 | Method for preparing three-layer embedded bifidobacterium microcapsules |
| CN103652891A (en) * | 2013-11-28 | 2014-03-26 | 浙江省农业科学院 | Lactobacillus casei embedding microcapsule and preparation method thereof |
-
2016
- 2016-01-29 CN CN201610064261.9A patent/CN105595359A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080138419A1 (en) * | 2003-04-15 | 2008-06-12 | Animal Technology Institute Taiwan | Method for preparing an orally administrable formulation for controlled release |
| CN1916161A (en) * | 2006-09-08 | 2007-02-21 | 肖雯娟 | Embedding protection method for beneficial bacteria of intestinal tract |
| CN101148642A (en) * | 2006-09-19 | 2008-03-26 | 国家淀粉及化学投资控股公司 | Probiotic/non-probiotic combinations |
| CN101683604A (en) * | 2009-08-21 | 2010-03-31 | 黑龙江大学 | Method for preparing lactobacillus microcapsules |
| CN102960598A (en) * | 2012-11-19 | 2013-03-13 | 陕西科技大学 | Method for preparing three-layer embedded bifidobacterium microcapsules |
| CN103652891A (en) * | 2013-11-28 | 2014-03-26 | 浙江省农业科学院 | Lactobacillus casei embedding microcapsule and preparation method thereof |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106667257A (en) * | 2016-11-22 | 2017-05-17 | 杭州益儒信息科技有限公司 | Water dispenser with probiotic slow release device |
| CN106417614A (en) * | 2016-11-22 | 2017-02-22 | 杭州益儒信息科技有限公司 | Probiotic slow releasing device |
| CN107549420A (en) * | 2017-10-30 | 2018-01-09 | 浙江同创越诚健康科技有限公司 | Probiotics candy and preparation method thereof |
| CN109846043A (en) * | 2017-11-30 | 2019-06-07 | 内蒙古伊利实业集团股份有限公司 | A kind of colon sustained release probiotics and preparation method thereof |
| CN109846043B (en) * | 2017-11-30 | 2023-04-07 | 内蒙古伊利实业集团股份有限公司 | Colon slow-release probiotics and preparation method thereof |
| CN110432495A (en) * | 2018-05-03 | 2019-11-12 | 内蒙古伊利实业集团股份有限公司 | A kind of probiotics preparation and preparation method thereof of acidproof resistance to bile salt |
| CN109182397B (en) * | 2018-09-18 | 2022-05-24 | 北京大伟嘉生物技术股份有限公司 | Method for improving yield of reuterin |
| CN109182397A (en) * | 2018-09-18 | 2019-01-11 | 北京大伟嘉生物技术股份有限公司 | A method of improving reuterin yield |
| CN109700781A (en) * | 2019-02-25 | 2019-05-03 | 绍兴同创生物科技有限公司 | A kind of probiotic microcapsule and preparation method thereof targeting enteron aisle |
| CN110123790A (en) * | 2019-05-17 | 2019-08-16 | 南京望知星医药科技有限公司 | A kind of clarithromycin slow-release micro-capsule and preparation method thereof |
| CN110604307A (en) * | 2019-08-02 | 2019-12-24 | 嘉必优生物技术（武汉）股份有限公司 | Probiotic microcapsule powder and preparation method and application thereof |
| CN110771898A (en) * | 2019-11-08 | 2020-02-11 | 厦门九和良方医药科技有限公司 | Probiotic microcapsule, preparation method and application thereof |
| CN111280449A (en) * | 2020-02-11 | 2020-06-16 | 浙江华康药业股份有限公司 | Intestinal slow-release sugar alcohol additive and preparation method and application thereof |
| CN111297911A (en) * | 2020-02-26 | 2020-06-19 | 青岛诺森生物技术有限责任公司 | Slow-release stress-resistant probiotic crystal ball and preparation method thereof |
| CN111317140A (en) * | 2020-05-06 | 2020-06-23 | 永安康健药业（武汉）有限公司 | Bile salt-resistant and gastric acid-resistant probiotic preparation as well as preparation method and application thereof |
| CN111920050A (en) * | 2020-09-01 | 2020-11-13 | 上海应用技术大学 | Double-layer microcapsule for regulating intestinal flora and preparation method thereof |
| CN115500516A (en) * | 2022-09-28 | 2022-12-23 | 江苏恒康生物科技有限公司 | Probiotic slow-release carrier, slow-release dropping pill, and preparation method and application thereof |
| CN115500516B (en) * | 2022-09-28 | 2023-11-07 | 江苏恒康生物科技有限公司 | Probiotics slow-release carrier, slow-release dripping pill, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105595359A (en) | Positioning and controlled-release microcapsule probiotics and preparation method thereof | |
| CN109619593B (en) | Probiotic double-layer microcapsule and preparation method thereof | |
| CN100469869C (en) | Embedding protection method for beneficial bacteria of intestinal tract | |
| CN101323850B (en) | Lactobacillus helveticus microcapsule, preparation and use thereof | |
| CN101289648B (en) | Enterococcus faecium microcapsule formulation and method for preparing same | |
| CN102370057B (en) | Lactobacillus microcapsule and preparation method thereof | |
| CN105567669B (en) | Probiotic microcapsule preparation and preparation method thereof | |
| Xing et al. | Effect of porous starch concentrations on the microbiological characteristics of microencapsulated Lactobacillus acidophilus | |
| CN106418547A (en) | Probiotics microcapsule and preparation method thereof | |
| TW201834673A (en) | Probiotic compositions comprising hericium erinaceus | |
| CN102228235A (en) | Method for preparing probiotics microcapsule and its application | |
| CN110179834A (en) | A kind of lactobacillus plantarum microcapsules and preparation method thereof | |
| CN111011867B (en) | Probiotic embedded particle and preparation method thereof | |
| CN103704719A (en) | Preparation method for probiotics microcapsule with high viable count | |
| CN107647251A (en) | A kind of preparation method of compound edible mushroom nutrient chewable tablet | |
| CN110731526A (en) | Method for embedding wall material by probiotics | |
| Hathi et al. | Methodological advances and challenges in probiotic bacteria production: Ongoing strategies and future perspectives | |
| CN111713685A (en) | Microcapsule wall material and application thereof in preparation of probiotic microcapsules | |
| EP4012017A1 (en) | Method for preparing pure plant-based microbial culture | |
| CN107949633A (en) | Novel lactobacillus species microorganism and the composition for animal feed for including it | |
| CN101160136A (en) | Hypotensive agent produced by cultivation of lactic acid bacterium | |
| CN104642746B (en) | A kind of preparation method of feeding lactobacillus micropill | |
| CN114806965B (en) | Probiotic agent for improving strain storage stability and preparation method and application thereof | |
| CN113230284B (en) | Synbiotic microencapsulated preparation based on multi-dimensional crosslinking and preparation method and application thereof | |
| CN113564067B (en) | Bifidobacterium subspecies F1-7 for promoting enterokinesia and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160525 |
|
| RJ01 | Rejection of invention patent application after publication |